Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
| ▸ | PDE4A | P27815 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PMM2 | O15305 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187989 | 0.88 | PDE1A (0.41) | PDE1APDE1BPDE4BPDE4DPDE4A | |
| SCHEMBL4183665 | 0.88 | PDE1A (0.53) | PDE1APDE1BTP53PDE4BPDE4D | |
| SCHEMBL4194544 | 0.80 | PDE1A (0.52) | PDE1APDE1BCYP1A2TP53POLB | |
| SCHEMBL4183635 | 0.78 | CYP1A2 (0.42) | PDE1APDE1BCYP1A2TP53POLB | |
| SCHEMBL4191899 | 0.78 | PDE1A (0.46) | PDE1APDE1BCYP1A2TP53POLB | |
| SCHEMBL4192481 | 0.77 | PDE1A (0.52) | PDE1APDE1BTP53POLBPDE4B | |
| SCHEMBL4185765 | 0.77 | PDE1A (0.46) | PDE1APDE1BCYP1A2TP53POLB | |
| SCHEMBL4193996 | 0.77 | AR (0.45) | PDE1APDE1BCYP1A2TP53POLB | |
| SCHEMBL4190247 | 0.77 | PDE1A (0.51) | PDE1APDE1BPDE4BPDE4DPDE4A | |
| SCHEMBL4189836 | 0.76 | TP53 (0.42) | PDE1APDE1BCYP1A2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8193356-B2 | Heterocycle compound, and production process and application thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1925617-A1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | PDE3B, PDE4B, PDE7A | PDE1A 26/4885PDE1B 21/4885CYP1A2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.